SCHEMBL69610

SCHEMBL69610

[c]1n[nH]cc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.40
AKT2 P31751 1/20 0.40
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.34
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
MAPK1 P28482 1/20 0.33
NOTUM Q6P988 1/20 0.32
SCN4A P35499 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NISCH Q9Y2I1 2/20 0.31
AURKA O14965 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
CASP1 P29466 1/20 0.31
TTK P33981 1/20 0.31
AURKB Q96GD4 1/20 0.31
INCENP Q9NQS7 1/20 0.31
IDO1 P14902 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17444512 0.71 AKT2 (0.43) AKT1AKT2MAPK1AURKAAURKB
SCHEMBL1967310 0.71 IDO1 (0.38) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL978671 0.69 ALDH1A1 (0.44) ALDH1A1ALOX15RAB9AMAPK1MEN1
SCHEMBL978864 0.67 ALDH1A1 (0.42) ALDH1A1ALOX15RAB9ANPC1MEN1
Biphenyl SCHEMBL4707139 0.61 ALDH1A1 (0.90) AKT1AKT2ALDH1A1RAB9ANPC1
Biphenyl SCHEMBL11347002 0.61 ALDH1A1 (0.90) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL5047733 0.59 ALDH1A1 (0.47) ALDH1A1ALOX15RAB9ANPC1MAPK1
Biphenyl SCHEMBL1358618 0.57 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM
Biphenyl SCHEMBL4002609 0.57 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM
Biphenyl SCHEMBL164 0.57 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO claimed
US-20230374014-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-23 US claimed
EP-3891145-B1 MODULATORS OF TREX1 CONSTELLATION PHARMACEUTICALS INC (US) 2023-04-12 EP claimed
EP-4153593-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-03-29 EP claimed
CN-115667265-A CGAS-inhibiting triazolopyrimidinone derivatives 豪夫迈·罗氏有限公司 2023-01-31 CN claimed
US-20220017502-A1 MODULATORS OF TREX1 CONSTELLATION PHARMACEUTICALS, INC. 2022-01-20 US claimed
WO-2021233852-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2021-11-25 WO claimed
EP-3891145-A1 MODULATORS OF TREX1 Constellation Pharmaceuticals, Inc. (US) 2021-10-13 EP claimed
CN-113396149-A Modulators of TREX1 星座制药公司 2021-09-14 CN claimed
US-11077113-B2 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes SPRINT BIOSCIENCE AB (SE) 2021-08-03 US claimed
WO-2001096339-A1 NOVEL TELOMERASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2001-12-20 WO claimed
EP-1042291-A1 ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP claimed
WO-1999031064-A1 ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO claimed
EP-0892788-A1 NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE BASF AKTIENGESELLSCHAFT (DE) 1999-01-27 EP claimed
EP-0874829-A1 AMINO ACID DERIVATIVES, THE PREPARATION AND USE THEREOF AS ENDOTHELIN ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1998-11-04 EP claimed
WO-1997038982-A1 NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE BASF AKTIENGESELLSCHAFT (DE) 1997-10-23 WO claimed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP claimed
WO-1997012878-A1 AMINO ACID DERIVATIVES, THE PREPARATION AND USE THEREOF AS ENDOTHELIN ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1997-04-10 WO claimed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO claimed
US-4310619-A LIGHT SENSITIVE ELEMENT COMPRISING A 5-PYRAZOLONE COUPLER FUJI PHOTO FILM CO., LTD. (JP) 1982-01-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077113-B2 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes PYCR1, GPR119, IL6 AKT1 3568/4885AKT2 3690/4885ALDH1A1 1644/4885
US-20230374014-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES CGAS, GLS2, GBA3 AKT1 2624/4885AKT2 3271/4885ALDH1A1 928/4885
US-20220017502-A1 MODULATORS OF TREX1 CFTR, SLC10A1, CYP27A1 AKT1 4181/4885AKT2 3914/4885ALDH1A1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.